Aquestive Therapeutics (NASDAQ:AQST) Rating Reiterated by HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $9.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 140.96% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Raymond James initiated coverage on Aquestive Therapeutics in a report on Thursday, March 28th. They issued an “outperform” rating and a $7.00 price objective for the company. Piper Sandler began coverage on Aquestive Therapeutics in a report on Thursday, April 11th. They set an “overweight” rating and a $10.00 target price for the company. Finally, JMP Securities upped their price objective on Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Friday, March 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Aquestive Therapeutics presently has a consensus rating of “Buy” and an average target price of $8.00.

Aquestive Therapeutics Price Performance

AQST opened at $3.74 on Tuesday. The firm has a 50 day simple moving average of $4.19 and a 200 day simple moving average of $2.84. Aquestive Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $6.23. The company has a market cap of $273.78 million, a price-to-earnings ratio of -26.68 and a beta of 2.87.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, March 5th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The business had revenue of $13.21 million for the quarter, compared to analysts’ expectations of $11.79 million. As a group, analysts expect that Aquestive Therapeutics will post -0.36 EPS for the current year.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 25,000 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $5.19, for a total value of $129,750.00. Following the completion of the sale, the insider now owns 1,040,371 shares in the company, valued at $5,399,525.49. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 8.39% of the company’s stock.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Armistice Capital LLC raised its stake in Aquestive Therapeutics by 314.5% in the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock valued at $7,344,000 after acquiring an additional 3,642,000 shares during the period. Essex Investment Management Co. LLC acquired a new position in shares of Aquestive Therapeutics in the fourth quarter valued at $1,709,000. Acadian Asset Management LLC raised its position in shares of Aquestive Therapeutics by 238.8% in the third quarter. Acadian Asset Management LLC now owns 550,484 shares of the company’s stock valued at $841,000 after purchasing an additional 388,017 shares during the period. Legato Capital Management LLC acquired a new stake in shares of Aquestive Therapeutics during the 4th quarter worth about $688,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Aquestive Therapeutics by 14.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock worth $379,000 after buying an additional 30,898 shares during the period. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.